Vannay Adám, Fekete Andrea, Müller Veronika, Strehlau Jürgen, Viklicky Ondrej, Veres Tibor, Reusz György, Tulassay Tivadar, Szabó Attila J
First Department of Pediatrics and Research Laboratory of the Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary.
Kidney Blood Press Res. 2004;27(2):105-13. doi: 10.1159/000077350. Epub 2004 Mar 17.
Vascular endothelial growth factor (VEGF) exerts cytoprotective, antiapoptotic and proangiogenic effects; its synthesis is induced by hypoxia, several cytokines and histamine. The effects of histamine and the H2 receptor antagonist ranitidine on renal VEGF and IL-6 synthesis were investigated in a well-established rat model of renal ischemia/reperfusion injury.
Following 7 days of pretreatment with histamine (H group; n = 12), ranitidine (R group; n = 10) or vehicle (controls; n = 13), the left vascular pedicle was clamped for 50 min in uninephrectomized male rats and survival assessed in the different treatment groups. Additionally, renal IL-6 mRNA expression, as well as VEGF mRNA and protein abundance were measured in the three treatment groups following pretreatment only, 2 and 16 h after 50 min of renal ischemia (n = 6/group/timepoint).
Ranitidine significantly increased, while histamine significantly decreased survival following renal ischemia. Renal IL-6 mRNA expression increased 2 h after reperfusion in all groups and decreased thereafter, with the lowest level observed in the R group. While VEGF mRNA did not change in controls, histamine increased, whereas ranitidine decreased its expression during the follow-up. Two hours after ischemia a twofold increase in renal VEGF protein abundance was observed in controls and the H group and significantly higher values were noted in the R group at this time point. A further increase in VEGF protein was only present in the H group 16 h after reperfusion.
These results indicate an important role of histamine in kidney damage following renal ischemia. The beneficial effects of ranitidine were partly mediated by decreased IL-6 and VEGF mRNA expression and significant early increase in renal VEGF abundance.
血管内皮生长因子(VEGF)具有细胞保护、抗凋亡和促血管生成作用;其合成受缺氧、多种细胞因子和组胺诱导。在一个成熟的大鼠肾缺血/再灌注损伤模型中,研究了组胺和H2受体拮抗剂雷尼替丁对肾VEGF和IL-6合成的影响。
用组胺(H组;n = 12)、雷尼替丁(R组;n = 10)或赋形剂(对照组;n = 13)预处理7天后,在单侧肾切除的雄性大鼠中夹闭左血管蒂50分钟,并评估不同治疗组的存活率。此外,仅在预处理后、肾缺血50分钟后2小时和16小时,在三个治疗组中测量肾IL-6 mRNA表达以及VEGF mRNA和蛋白丰度(每组/每个时间点n = 6)。
雷尼替丁显著提高了肾缺血后的存活率,而组胺则显著降低了存活率。所有组再灌注2小时后肾IL-6 mRNA表达均增加,此后降低,R组观察到的水平最低。虽然对照组中VEGF mRNA没有变化,但组胺使其增加,而雷尼替丁在随访期间降低了其表达。缺血2小时后,对照组和H组肾VEGF蛋白丰度增加了两倍,此时R组的值显著更高。再灌注16小时后,VEGF蛋白进一步增加仅出现在H组。
这些结果表明组胺在肾缺血后肾损伤中起重要作用。雷尼替丁的有益作用部分是通过降低IL-6和VEGF mRNA表达以及肾VEGF丰度的显著早期增加介导的。